While tremendous relief comes from successfully battling cancer, survivors can also experience cognitive impairments caused by the disease and its treatment. Up to 70% of survivors experience trouble ...
A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...
The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...
CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and ...
ANX007 targets C1q to inhibit the complement cascade, reducing neuroinflammation and protecting photoreceptors in AMD and GA. The ARCHER trial showed significant vision loss reduction, with a 73% risk ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to ...
Complement Therapeutics GmbH (CTx), a biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) ...
What happens when the relief of surviving brain cancer is accompanied by struggles to remember and concentrate, negatively ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback